# EDGAR Filing Document

**Accession Number:** 0001717915
**File Stem:** 0000920148-26-000033
**Filing Date:** 2026-2
**Character Count:** 11079
**Document Hash:** 6dcaa1fdb058aa92fd25647616b18d98
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000920148-26-000033.hdr.sgml**: 20260210

**ACCESSION NUMBER**: 0000920148-26-000033

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260206

**FILED AS OF DATE**: 20260210

**DATE AS OF CHANGE**: 20260210

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Caveney Brian J
- **CENTRAL INDEX KEY:** 0001717915

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11353
- **FILM NUMBER:** 26615517

**MAIL ADDRESS:**
- **STREET 1:** 531 SOUTH SPRING STREET
- **CITY:** BURLINGTON
- **STATE:** NC
- **ZIP:** 27215
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LABCORP HOLDINGS INC.
- **CENTRAL INDEX KEY:** 0000920148
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 992588107
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 358 S MAIN ST
- **CITY:** BURLINGTON
- **STATE:** NC
- **ZIP:** 27215
- **BUSINESS PHONE:** 3362291127

**MAIL ADDRESS:**
- **STREET 1:** 358 S MAIN ST
- **CITY:** BURLINGTON
- **STATE:** NC
- **ZIP:** 27215

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LABORATORY CORP OF AMERICA HOLDINGS
- **DATE OF NAME CHANGE:** 19950504

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NATIONAL HEALTH LABORATORIES HOLDINGS INC
- **DATE OF NAME CHANGE:** 19940314

## Ex-24

```

EXHIBIT 24

                                   LABCORP HOLDINGS INC.
					SECTION 16
				     POWER OF ATTORNEY
                                   -----------------

Know by all these presents, that the undersigned hereby constitutes and
appoints Kathryn W. Kyle, the undersigned's true and lawful
attorney-in-fact and agent to:

(1)  execute for and on behalf of the undersigned, in the undersigned's capacity
     as an officer of Labcorp Holdings Inc. (the "Company"), Forms 3, 4, and 5
     in accordance with Section 16(a) of the Securities Exchange Act of 1934,
     as amended, and the rules thereunder;

(2)  do and perform any and all acts for and on behalf of the undersigned which
     may be necessary or desirable to complete and execute any such Form 3,
     Form 4, or Form 5, complete and execute any amendment or amendments
     thereto and any instrument, contract, document or other writing, or in
     connection with any such Form 3, Form 4, or Form 5 or amendments thereto,
     and timely file any such form, with all exhibits thereto, and other
     documents in connection therewith, including this power-of-attorney, with
     the United States Securities and Exchange Commission (the "SEC") and any
     stock exchange or similar authority, including, but not limited to,
     executing a Form ID for and on behalf of the undersigned and filing such
     Form ID with the SEC; and

(3)  take any other action of any type whatsoever in connection with the
     foregoing which, in the opinion of the attorney-in-fact, may be of benefit
     to, in the best interest of, or legally required by, the undersigned, it
     being understood that the documents executed by the attorney-in-fact on
     behalf of the undersigned pursuant to this Power of Attorney shall be in
     such form and shall contain such terms and conditions as the attorney-in-
     fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to the attorney-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that the attorney-in-fact, or the attorney-
in-fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted. The
undersigned acknowledges that the foregoing attorney-in-fact, in serving in
such capacity at the request of the undersigned, is not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall be effective immediately, and shall remain in
full force and effect until the undersigned is no longer required to file
Forms 3, 4, and 5 with respect to the undersigned's holdings of and
transactions in securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 19th day of January, 2026.

                                    /s/ Brian J. Caveney
                                   --------------------------
                                   Brian J. Caveney

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Caveney Brian J<br><sub>(Last) (First) (Middle)</sub><br>531 SOUTH SPRING STREET<br><sub>(Street)</sub><br>BURLINGTON, NC 27215<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-06 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EVP, Pres of ED, CMO & CSO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>LABCORP HOLDINGS INC. [ LH ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-02-06 |  | M |  | 670 | A | <sup>(1)</sup> | 30838.9234<sup>(2)</sup> | D |  |
| Common Stock | 2026-02-06 |  | F<sup>(3)</sup> |  | 209 | D | $277.20 | 30629.9234 | D |  |
| Common Stock | 2026-02-07 |  | M |  | 517 | A | <sup>(1)</sup> | 31146.9234 | D |  |
| Common Stock | 2026-02-07 |  | M |  | 111 | A | <sup>(1)</sup> | 31257.9234 | D |  |
| Common Stock | 2026-02-09 |  | F<sup>(3)</sup> |  | 148 | D | $274.01 | 31109.9234 | D |  |
| Common Stock | 2026-02-09 |  | F<sup>(3)</sup> |  | 32 | D | $274.01 | 31077.9234 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | <sup>(1)</sup> | 2026-02-06 |  | M |  |  | 670 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 670 | $0 | 3518<sup>(5)</sup> | D |  |
| Restricted Stock Unit | <sup>(1)</sup> | 2026-02-07 |  | M |  |  | 517 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 517 | $0 | 3001<sup>(5)</sup> | D |  |
| Restricted Stock Unit | <sup>(1)</sup> | 2026-02-07 |  | M |  |  | 111 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 111 | $0 | 2890<sup>(5)</sup> | D |  |

---

### Footnotes:

(1) Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc.  Common Stock.

(2) Amount includes 57.1306 shares acquired on June 30, 2025 under the Labcorp Holdings Inc. Amended and Restated 2016 Employee Stock Purchase Plan and 45.1355 shares acquired on December 31, 2025 under the Labcorp Holdings Inc. 2025 Employee Stock Purchase Plan.

(3) Stock withholding to satisfy tax withholding obligations.

(4) The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025.

(5) This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

(6) The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Kathryn W. Kyle, Attorney-in-Fact for Brian J. Caveney  
**Date:** 2026-02-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**